Biogen Idec Assumes Aviptadil Development Responsibility From Mondobiotech
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III product would join a growing pulmonary arterial hypertension market.
You may also be interested in...
Biogen Idec Planning Phase III Studies For Heart Failure Candidate Adentri
A1 adenosine receptor antagonist showed promise in Phase II as an addition to standard therapy for increasing sodium excretion, protecting renal function, according to JACC study.
Biogen Idec Planning Phase III Studies For Heart Failure Candidate Adentri
A1 adenosine receptor antagonist showed promise in Phase II as an addition to standard therapy for increasing sodium excretion, protecting renal function, according to JACC study.
Biogen Idec Partners With Cardiokine On Vasopressin Antagonist For Hyponatremia
Phase III trials of the oral drug, which will start this year, are expected to take two years to complete, Biogen says.